Description

Simple

Clinical

Overview

Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals. It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Mebanazine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with (S)-Warfarin.
1-benzylimidazole
The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Mebanazine.
2,4-thiazolidinedione
Mebanazine may increase the hypoglycemic activities of 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylamphetamine
Mebanazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
Mebanazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
Mebanazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin
The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
Mebanazine may increase the hypertensive activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Mebanazine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Mebanazine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Mebanazine.
Abciximab
The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Abciximab.
Abediterol
The risk or severity of adverse effects can be increased when Mebanazine is combined with Abediterol.
Acarbose
Mebanazine may increase the hypoglycemic activities of Acarbose.
Acebutolol
Mebanazine may increase the hypotensive activities of Acebutolol.
Aceclofenac
The risk or severity of hypertension can be increased when Aceclofenac is combined with Mebanazine.
Acemetacin
The risk or severity of hypertension can be increased when Mebanazine is combined with Acemetacin.
Acenocoumarol
The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Acenocoumarol.
Acepromazine
The risk or severity of extrapyramidal symptoms can be increased when Acepromazine is combined with Mebanazine.
3 References
  1. 1 . Gilmour SJ: Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry. 1965 Sep;111(478):899-902.PubMed: 5889715
  2. 2 . Barker JC, Jan IA, Enoch MD: A controlled trial of mebanazine ('Actomol') in depression. Br J Psychiatry. 1965 Nov;111(480):1095-100.PubMed: 5320546
  3. 3 . Knott F: A preliminary trial of mebanazine in depressive states. J New Drugs. 1965 Nov-Dec;5(6):345-7.PubMed: 5327282